Propanc Biopharma appoints Carlo Campiciano to Board, replacing retiring director Annie Van Broekhoven

Propanc Biopharma, Inc.

Annie Van Broekhoven retired from Board effective July 8, 2026.
Carlo Campiciano appointed to fill vacancy; he is a qualified accountant and former CFO of MedAdvisor.
Director agreement provides $45,000 annual cash compensation paid quarterly.
Equity compensation of 0.5% to 4.99% based on milestone achievements.
Campiciano is independent per Nasdaq/NYSE American standards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.